Unlock instant, AI-driven research and patent intelligence for your innovation.

Epitopes of hepatitis C virus

a technology of hepatitis c virus and epitopes, which is applied in the field of t cell immunity to viral antigens, can solve the problems of no vaccine to prevent hcv infection in humans, and achieve the effects of low cd45ra, increased proliferation, and high expression of ccr7

Inactive Publication Date: 2008-02-21
LAUER GEORG +2
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a composition containing HCV epitopes that can be used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The composition contains a mixture of peptides that bind to multiple HLA class I molecules, ensuring that it can elicit an immune response in a genetically-diverse population. The peptides are optimized for size and HLA binding, and are derived from natural HCV proteins. The composition can be used to stimulate CTLs and inhibit viral replication in infected cells. The peptides are also useful in identifying and monitoring the progress of HCV infection in individuals.

Problems solved by technology

At present, there is no vaccine to prevent HCV infection in humans.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Epitopes of hepatitis C virus
  • Epitopes of hepatitis C virus
  • Epitopes of hepatitis C virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0042] The HCV-specific CD8+ T-cell response plays a critical role in protecting against and combating hepatitis C-virus infection. Prior to the invention, studies of these responses relied on the analysis of a small number of predicted HCV epitopes, mostly restricted by HLA A2. In order to determine the actual breadth and magnitude of CD8+ T-cell responses in the context of diverse HLA class I alleles, a comprehensive analysis of responses to all expressed HCV proteins was carried out. A panel of 301 overlapping peptides was used to analyze PBMC from a cohort of 14 anti-HCV positive, HLA A2 positive individuals in an Elispot assay. Only 4 subjects had detectable HLA A2 restricted responses in PBMC, and only 3 of 19 predicted A2 epitopes were targeted, all of which were confirmed by tetramer analysis. In contrast, 9 of 14 persons had responses by more comprehensive analysis, with many responses directed against previously unreported epitopes. These results indicate that circulating ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
pHaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

The invention provides compositions containing HCV epitopes, which are recognized by cytotoxic T lymphocytes. Such polypeptides are used in prophylactic vaccines, immunotherapies, and assays to monitor the progress or success of immune interventions. The compositions are optimized to elicit an immune response in a genetically-diverse population of individuals.

Description

PRIORITY CLAIM [0001] This application claims priority to provisional patent application 60 / 381,273, the entire contents of which are hereby incorporated by reference.STATEMENT AS TO FEDERALLY SPONSORED RESEARCH [0002] This invention was made with U.S. Government support under a National Institutes of Health grant number AI31563. The government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] The invention relates to T cell immunity to viral antigens. [0004] Hepatitis is a disorder involving inflammation of the liver. Hepatitis C(HCV) is a form of hepatitis caused by an RNA virus. This pathogen accounts for many of the hepatitis cases previously referred to as non-A, non-B hepatitis. HCV is believed to cause between 150,000 and 250,000 new cases of hepatitis in the United States each year. Hemophiliacs and drug abusers are at the greatest risk, but anyone can contract the disease. Transmission often occurs through a blood transfusion, administration of blood pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/29A61P31/14C07K7/06C07K7/08C12Q1/70A61K39/00A61K39/12C07KC07K14/18G01N33/569
CPCA61K2039/57G01N33/56983C12N2770/24222C07K14/005A61P31/14
Inventor LAUER, GEORGOUCHI, KEIWALKER, BRUCE D.
Owner LAUER GEORG